Dynamic Technology Lab Private Ltd lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 44.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,575 shares of the medical research company’s stock after selling 1,242 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Bio-Rad Laboratories were worth $481,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Quadrant Capital Group LLC boosted its stake in shares of Bio-Rad Laboratories by 205.9% in the 1st quarter. Quadrant Capital Group LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 70 shares in the last quarter. Financial Gravity Wealth Inc. acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $57,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $81,000. Enlightenment Research LLC acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $70,000. Finally, Osborn Williams & Donohoe LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at $98,000. Institutional investors own 64.34% of the company’s stock.
Several brokerages have recently commented on BIO. Barclays boosted their target price on shares of Bio-Rad Laboratories from $315.00 to $340.00 and gave the company an “overweight” rating in a research note on Friday, March 1st. Deutsche Bank lifted their price target on Bio-Rad Laboratories from $330.00 to $350.00 and gave the company a “buy” rating in a report on Friday, March 1st. Zacks Investment Research raised Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $360.00 price target for the company in a report on Wednesday, March 6th. Finally, ValuEngine raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $365.00.
In other Bio-Rad Laboratories news, EVP Timothy S. Ernst sold 345 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $290.00, for a total transaction of $100,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 27.84% of the company’s stock.
Bio-Rad Laboratories stock opened at $297.31 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.57 and a quick ratio of 3.24. Bio-Rad Laboratories, Inc. has a 12-month low of $220.05 and a 12-month high of $345.15. The stock has a market capitalization of $8.82 billion, a P/E ratio of 50.91, a price-to-earnings-growth ratio of 2.76 and a beta of 1.22.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported $1.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.12 by $0.53. The business had revenue of $553.98 million during the quarter, compared to analysts’ expectations of $548.82 million. Bio-Rad Laboratories had a return on equity of 4.15% and a net margin of 24.84%. As a group, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 7.15 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Zolmax and is the property of of Zolmax. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://zolmax.com/investing/bio-rad-laboratories-inc-nysebio-stake-lowered-by-dynamic-technology-lab-private-ltd/3112797.html.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Recommended Story: What is total return in investing?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.